Heritage Global Partners To Manage Global Online Auction Of Nuclea Biotechnologies’ FDA-Cleared Diagnostic Intellectual Property Assets And Materials

SAN DIEGO--(BUSINESS WIRE)--Heritage Global Partners (“HGP”), a worldwide leader in asset advisory and auction services and a subsidiary of Heritage Global Inc. (OTCQB: HGBL, CSE: HGP), today announced it will manage a global online auction of the complete Intellectual Property (“IP”) and related assets of Nuclea Biotechnologies Inc. (“Nuclea” or “the Company”). Founded in 2005, Nuclea, was a leading innovator in mass spectrometry testing, engaged in the development and commercialization of clinical In Vitro Diagnostic (IVD) and Research Use Only (RUO) assays used in the early detection and monitoring of prostate and breast cancer, diabetes and other metabolic syndromes within the oncology and endocrinology fields of medicine.

The global online sale will begin on January 18, 2017 and will feature the Nuclea’s licensing, patents and materials for Human Epidermal Growth Factor Receptor 2 (HER2) – one of the only Food and Drug Administration (FDA)-cleared tests for monitoring and managing metastatic breast cancer – Epidermal Growth Factor Receptor (EGFr) and other valuable assays. The sale will also feature other finished goods, kits and controls used for the diagnostic testing and research of prostate and breast cancer, diabetes and other metabolic syndromes within the oncology and endocrinology fields of medicine. A data room with detailed lot descriptions and patent information is available on HGP’s website.

Nuclea Biotechnologies Global Online Asset Auction

(Subject to US Bankruptcy Court Approval, Case #16-11945 -CSS Nuclea Biotechnologies, Inc.)

January 18, 2017 (07:00 am PST) – January 19, 2017 (12:00 pm PST)

http://www.hgpauction.com/auctions/87300/nuclea-biotechnologies/

For questions and auction data room access contact Craig Thompson, VP of Sales.

“Our upcoming global online auction sale features an unprecedented offering of biotechnology assets including Nuclea’s valuable FDA-cleared patents, kits and materials currently utilized by oncologists and endocrinologists to diagnose and research metabolic syndromes. This is a rare opportunity for biotechnology companies to acquire exceptional assets from a former leader in mass spectrometry. We are already receiving strong interest from worldwide buyers for the intellectual property and materials of HER2, EGFR and other Nuclea assays and expect participation levels will continue to grow as we approach the auction launch date,” stated Craig Thompson.